Next Article in Journal
Influence of Acute Exercise on DNA Repair and PARP Activity before and after Irradiation in Lymphocytes from Trained and Untrained Individuals
Previous Article in Journal
Ubiquitination and Long Non-coding RNAs Regulate Actin Cytoskeleton Regulators in Cancer Progression
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 20
Issue 12
10.3390/ijms20122998
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Transcriptomic Insights into the Response of the Olfactory Bulb to Selenium Treatment in a Mouse Model of Alzheimer’s Disease

by
Rui Zheng
,
Zhong-Hao Zhang
,
Yu-Xi Zhao
,
Chen Chen
,
Shi-Zheng Jia
,
Xian-Chun Cao
,
Li-Ming Shen
,
Jia-Zuan Ni
and
Guo-Li Song
*
Shenzhen Key Laboratory of Marine Bioresources and Ecology, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(12), 2998; https://doi.org/10.3390/ijms20122998
Submission received: 20 May 2019 / Revised: 5 June 2019 / Accepted: 17 June 2019 / Published: 19 June 2019
(This article belongs to the Section Molecular Neurobiology)
Browse Figures
Review Reports Versions Notes

Abstract

:
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder characterized by the presence of extracellular senile plaques primarily composed of Aβ peptides and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau proteins. Olfactory dysfunction is an early clinical phenotype in AD and was reported to be attributable to the presence of NFTs, senile Aβ plaques in the olfactory bulb (OB). Our previous research found that selenomethionine (Se-Met), a major form of selenium (Se) in organisms, effectively increased oxidation resistance as well as reduced the generation and deposition of Aβ and tau hyperphosphorylation in the olfactory bulb of a triple transgenic mouse model of AD (3×Tg-AD), thereby suggesting a potential therapeutic option for AD. In this study, we further investigated changes in the transcriptome data of olfactory bulb tissues of 7-month-old triple transgenic AD (3×Tg-AD) mice treated with Se-Met (6 µg/mL) for three months. Comparison of the gene expression profile between Se-Met-treated and control mice revealed 143 differentially expressed genes (DEGs). Among these genes, 21 DEGs were upregulated and 122 downregulated. The DEGs were then annotated against the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. The results show that upregulated genes can be roughly classified into three types. Some of them mainly regulate the regeneration of nerves, such as Fabp7, Evt5 and Gal; some are involved in improving cognition and memory, such as Areg; and some are involved in anti-oxidative stress and anti-apoptosis, such as Adcyap1 and Scg2. The downregulated genes are mainly associated with inflammation and apoptosis, such as Lrg1, Scgb3a1 and Pglyrp1. The reliability of the transcriptomic data was validated by quantitative real time polymerase chain reaction (qRT-PCR) for the selected genes. These results were in line with our previous study, which indicated therapeutic effects of Se-Met on AD mice, providing a theoretical basis for further study of the treatment of AD by Se-Met.

1. Introduction

Alzheimer’s disease (AD) is a neurodegenerative disease affecting a large population worldwide and is mainly characterized by progressive memory loss along with various other symptoms [1]. It involves nearly all the systems of the human body, such as the nervous system, endocrine system, and the immune system [2,3].
Studies have demonstrated that olfactory function decreases with aging, and the decline in olfaction is a common clinical phenotype of AD [4]. Olfactory dysfunction is prevalent in AD patients, and the functions of odor detection, discrimination, and identification are affected earlier than the decrease in cognitive ability [5]. Thus, olfactory dysfunction is considered a prodromal symptom of AD and has been proposed as a predicting factor of cognitive impairments [6]. The olfactory bulb is the first place that processes olfactory information received from the axons of olfactory receptor neurons [7]. It has been suggested that the olfactory bulb could be a starting point of pathology in AD [8]. In our previous study, we showed that selenomethionine (Se-Met), a major form of selenium in organisms, effectively increased oxidation resistance as well as reduced the production and deposition of Aβ and tau hyperphosphorylation in the hippocampus, cortex, and also the olfactory bulb of a triple transgenic mouse model of AD (3×Tg-AD) [9,10]. In addition, we determined the selenium levels in the tissues and organs of AD mice before and after treatment with Se-Met, and found that the level of selenium in brain tissue and olfactory bulb tissue increased significantly, indicating that selenium plays a biological role in the process of Se-Met treatment of AD mice [11]. Various mechanisms have been proposed to account for the therapeutic effects of Se-Met on AD, such as Se-Met-activated autophagy to eliminate Aβ and tau, promotion of neurogenesis in the hippocampus and reduction of inflammation and oxidative stress in the brain [9,12,13], but the foremost mechanism of the effect of Se-Met on the olfactory bulb is still unclear.
Gene expression analysis is a useful tool in the study of neurodegenerative disease. To date, the majority of studies in the literature highlighted interesting genes on the basis of differential mRNA expression profile between control and experimental samples displaying an advantageous trait or the response to drug stimuli [14].
In this study, we investigated changes in the transcriptome data of olfactory bulb tissues in 7-month-old 3×Tg-AD mice after treatment by Se-Met for three months. We first searched for differentially expressed genes (DEGs) that were significantly altered (p < 0.05), followed by Gene Ontology (GO) analysis to find the specific function of the genes and Kyoto encyclopedia of genes and genomes (KEGG) analysis to bioassay enrichment of gene sets. To our knowledge, this is the first effort to study transcriptome sequences in the mouse olfactory bulb that may help understand the role of Se-Met in the treatment of AD.

2. Results

2.1. Differential Gene Expression between 3×Tg-AD Mice and Se-Met-Treated 3×Tg-AD Mice

We selected the differently expressed genes according to the two criteria of (| log (fold change) |> 1) and the significance level (p < 0.05). The statistics of the number of significant differentially expressed genes are shown in Figure 1. One hundred forty-three genes were differentially expressed in the Se-Met-treated AD mice compared to the control mice, with 21 genes upregulated and 122 genes downregulated (Table S1).

2.2. Overrepresentation Analysis

To determine the function of DEGs, a Gene Ontology (GO) enrichment analysis was performed (Table 1). GO results showed that DEGs were involved primarily in cellular responses to xenobiotic stimuli, flavonoid glucuronidation and glucuronate metabolic processes according to biological processes (BP). In terms of the cellular component (CC) annotation, “extracellular region”, “membrane-bounded vesicle” and “basolateral plasma membrane” showed large enrichment. Regarding the molecular function (MF) annotation, “transferase activity and transferring glycosyl groups”, “epidermal growth factor receptor binding”, “peptide hormone receptor binding” and “immunoglobulin binding” showed large enrichment.
To further determine which pathways could be directly affected by Se-Met treatment in 3xTg AD mice, DEGs were analyzed using the KEGG PATHWAY database. A Benjamini–Hochberg corrected p-value <0.05 was deemed significant. The DEGs were observed to be mainly part of signaling pathways including “metabolic”, “pentose and glucuronate interconversions”, “nicotinate and nicotinamide metabolism” and “ascorbate and aldarate metabolism” (Figure 2). A substantial number of other DEGs were also found to participate in different metabolic pathways such as “TNF signaling pathway” and “amino acids metabolism”.
To better clarify the genetic differences between Se-Met-treated and control AD mice, we selected the Top 20 upregulated and downregulated genes in the differential genes according to the p-value. The 20 genes upregulated with the highest fold-change in the Se-Met–treated group compared to the control group are shown in Table 2, and those downregulated are shown in Table 3.
To further investigate the effect of Se-Met on 3×Tg-AD mice, GO and KEGG analyses were performed on the top 20 up-regulated and the top 20 down-regulated genes, respectively. It was found that in the up-regulated genes, the biological processes most significantly affected by Se-Met are “positive regulation of secretion, neuropeptide signaling pathway and glial cell proliferation. In the cell components, Se-Met predominantly exerted its effects in the “extracellular region” and “neuron part”, etc. In molecular functions, Se-Met mainly affected “receptor binding” “G-protein coupled receptor binding” and “neuropeptide receptor binding” (Figure 3). In addition, in KEGG analysis, the “metabolism of cofactor and vitamins” signaling pathway was also significantly affected.
In the top 20 down-regulated genes, the biological processes “cell activation” and “response to cytokine” were most significantly affected. In the cell components, Se-Met mainly acted in the “extracellular region” and “extracellular space”. In the molecular functions, Se-Met mainly affected “receptor binding” “cell adhesion molecule binding” and “calcium-dependent protein binding” (Figure 4). In addition, through KEGG analysis, Se-Met mainly affected “transporters signal pathways” such as “cytokine–cytokine receptor interaction” and “nicotine addiction”.

2.3. Real-Time PCR Validation of Differentially Expressed Genes

To further verify the reliability of sequencing, nine genes were randomly selected from the top 20 upregulated and downregulated genes for qPCR experiments. The selections included upregulated genes, such as adenylate cyclase activating polypeptide 1 (Adcyap1), amphiregulin (Areg), secretogranin II (Scg2), fatty acid binding protein 7 (Fabp7), ets variant 5 (Evt5), and galanin (Gal), and downregulated genes, such as leucine-rich alpha-2-glycoprotein 1 (Lrg), secretoglobin family 3A member 1 (Scgb3a1), and peptidoglycan recognition protein 1 (Pglyrp1). The results further validated the result of deep sequencing (Figure 5).

3. Discussion

In the 7-month-old 3×Tg-AD mice, some of the early pathological features of AD began to appear, such as slightly decreased cognitive function, and the formation of Aβ [15]. Moreover, olfactory deficits also occurred before the clinical onset of cognitive deficits and coincided with AD pathology [16]. In our previous study [10], we found that, in addition to an improvement in cognitive ability, Se-Met treatment also induced a significant neuropathological improvement in the OB of 7-month-old 3×Tg-AD mice. Thus, AD-associated pathology in OB is also sensitive to pharmacological interventions, such as for those in the cortex and hippocampus [13]. To further clarify the effect of Se-Met treatment on neuropathology and behavioral changes at this time point, we carried out an OB transcriptome analysis, although using this method involves risks of identifying subtle changes at the level of local gene expression that may not be representative of whole brain gene expression.
We found in the GO and KEGG analysis of the total differential genes, “transferase activity and transferring glycosyl groups”, “epidermal growth factor receptor binding”, “peptide hormone receptor binding” and “immunoglobulin binding” showing large enrichment. The DEGs were observed to be mainly involved in signaling pathways including “metabolic”, “pentose and glucuronate interconversions” and “ascorbate and aldarate metabolism”. Many patients with Alzheimer’s disease have associated vascular disease [17], including changes in blood rheology: hyperglycemia, abnormal platelet function, and elevated blood coagulation factors, resulting in increased blood viscosity [18,19]. At the same time, pathological changes, including capillary basement membrane thickening, endothelial cell swelling and hyperplasia [20], thickening of the wall, glycoprotein deposition [20,21], which causes ischemia and hypoxia of nerve tissue, also lead to nerve tissue necrosis and dysfunction. We performed GO analysis of the total differential genes and found that Se-Met has a certain effect on “epidermal growth factor receptor binding” and “peptide hormone receptor binding”, which suggests a potential beneficial effect on vascular endothelial cells. Vascular endothelial cells are the main cellular components that constitute the vascular wall and the blood-brain barrier [22]. They secrete various vasoactive substances, including endothelin, nitric oxide, and prostaglandins, which play important roles in the processes of eliminating brain wastes [23]. Thus, the improvement of vascular endothelial cells might also play a role in the therapeutic effect of Se-Met on AD.
The brain is the organ with the highest cholesterol content and contains 25% of the unesterified cholesterol in the body [24]. Due to the presence of the blood-brain barrier, almost all cholesterol in the brain is self-synthesized [25]. Neurons are not able to efficiently synthesize cholesterol, and the synthesis of cholesterol is mainly dependent on astrocytes [26]. Most of the cholesterol is transported to neurons by APOE (apolipoprotein E) containing lipoproteins [27]. The increase of cholesterol level in the neuronal cell leads to the increase of β-secretase activity and Aβ generation [28,29], the phosphorylation of Tau [30,31], and a reduced level of synaptophysin [32]. Through the enrichment of KEGG, we found that Se-Met could effectively improve the lipid metabolism in 3×Tg-AD mice. Therefore, we speculated that the improving effect of Se-Met on lipid metabolism might contribute to its effect of protecting neurons and ameliorating the cognitive deficit in AD mice.

3.1. Upregulated Genes in 3×Tg-AD (Se-Met) Mice

This work has identified several key genes upregulated after treatment with Se-Met, including Adcyap1, which encodes a member of the glucagon superfamily of hormones that have important roles in the pathogenesis of AD [33]. Pituitary adenylate cyclase activating polypeptide (PACAP) is a protein encoded by the Adcypa1 gene that is expressed primarily in sensory neurons, sympathetic preganglionic neurons, and parasympathetic ganglionic neurons. PACAP has been shown to function as a neuro-hormone, a neurotransmitter, and a neurotrophic factor [34]. It has been demonstrated that PACAP levels start to decline before the onset of AD dementia [35]. This reduction in PACAP level is region specific, targeting vulnerable areas in the AD brain [36]. In addition, PACAP binds to PAC1 receptors and activates adenylate cyclase (AC)-linked signal transduction pathways in cells. PACAP triggers anti-apoptotic transcriptional target gene expression and inhibits apoptotic signaling responses, including ROS generation, mitochondrial Bax and cytochrome C release, and subsequent caspase-3 activation [37,38].
Another upregulated DEG, Areg, encodes a member of the epidermal growth factor (EGF) family that is proteolytically processed to generate a mature protein [39]. EGF was reported to prevent Aβ-induced damage to the cerebrovascular system, thus implicating angiogenic pathways as potential therapeutic targets for AD [40]. The Areg-encoded protein is a ligand of the epidermal growth factor receptor (EGFR) and has been shown to play a role in immunity, inflammation, tissue repair, and lung and mammary gland development [41]. It was reported that EGFR expression was significantly increased in the OB of AD and that EGFR signaling was necessary for olfactory learning and discrimination [42].
Scg2 is a secreted neuroendocrine marker observed in prostatic small-cell neuroendocrine carcinoma [43]. It has been demonstrated that the levels of the Scg2-derived peptide secretoneurin decreased in cerebrospinal fluid (CSF) in AD mice [43]. Secretoneurin induces dopamine release from nigrostriatal neurons, influences neurite outgrowth, exerts chemotactic effects on monocytes, eosinophils and endothelial cells, and has angiogenic effects [44]. Moreover, Scg2 was also reported to be involved in many biological processes, such as induction of MAPK cascade and negative regulation of extrinsic apoptotic signaling pathway [45,46]. Therefore, Se-Met might exert its anti-AD effects through inhibition of apoptotic signaling responses, activation of EGFR signaling and increasing the secretoneurin level.
Evt5 plays an important role in cell proliferation and differentiation [47], such as positive regulation of glial cell proliferation, regulation of DNA transcription, and cellular response to oxidative stress [48,49]. Fabp7 is known as a brain lipid-binding protein. It has been demonstrated that the synthesis of Fabp7 by astrocytes in neurogenic niches has implications for neurogenesis in an AD model [50]. Moreover, both upstream modulators of Fabp7 expression including transcription factors Notch and Pax6 and downstream mediators of Fabp7 such as fatty acid-binding proteins, were reported to enhance the cellular uptake of retinoic acid, modulate gene transcription and promote nerve regeneration [51,52]. In AD, the disruption of neurogenesis results in the loss of normal neural function and the inability to generate a sufficient number of neurons, which ultimately leads to brain dysfunction [53]. Induction of neurogenesis can stimulate self-repair mechanisms in the brain to repair brain regions suffering from degenerative damage. There are a large number of regenerative and differentiated neural stem cells in OB [54]. Our previous research found that Se-Met promotes neurogenesis in the hippocampus [12]. Therefore, we hypothesize that Se-Met could enhance Evt5 and Fabp7 expression and promote neuroregeneration in OB.
Galanin (Gal) is an endogenously expressed neuropeptide [55] and is known to be involved in several prominent processes of the nervous system, such as memory function, regulation of hypothalamopituitary hormones, inflammation and neuroprotection [56,57]. Gal has been reported to have neuroprotective roles in several cases, such as traumatic brain injury, β-amyloid poisoning, glutamate-induced excitotoxicity and high-glucose-induced apoptosis [58]. The upregulation of Gal and endocannabinoid systems supported the hypothesis of their neuroprotective roles, which are established prior to the onset of clear clinical cognitive symptoms of the disease [59].

3.2. Downregulated Genes in 3×Tg-AD (Se-Met) Mice

Lrg1 is reported to be highly elevated in idiopathic normal pressure hydrocephalus (iNPH) and is believed to be an iNPH-specific candidate biomarker in cerebro-spinal fluid (CSF) [60,61]. Cognitive impairment due to iNPH initially presents as frontal lobe dysfunction with deficits in attention, execution, and thinking. In an advanced stage of iNPH, short-term memory is impaired like that in AD. Differentiating iNPH from Alzheimer’s disease (AD) is difficult when the cognitive function of the patient is highly impaired [61]. Therefore, we speculate that Lrg1 has a similar function in AD. It is also reported that the expression level of Lrg1 is correlated with inflammation [62]. Therefore, a significant decrease in the Lrg1 expression level after Se-Met treatment of 3xTg AD mice confirmed that Se-Met has a role in alleviating the inflammation of AD, which agrees with our previous results [9,10].
Pglyrp1 (peptidoglycan recognition protein 1) is a neutrophil granule protein with antibacterial properties, and when multimerized, it becomes a functional ligand of a triggering receptor expressed on myeloid cells (TREM-1), a cell-surface receptor involved in innate immune activation and amplification of inflammatory response to bacterial infections [63]. In addition, Pglyrp1 was also reported to be dysregulated in AD patient sera samples and could be a potential serum biomarker for the identification of AD [64].
Scgb3a1 encodes a small secreted protein that plays a role in inhibiting cell growth [65]. Spliced transcript variants encoding multiple isoforms have been observed for this gene [66]. Scgb3a1 is a suggested tumor suppressor gene that inhibits cell growth and invasion and is methylated and down-regulated in many epithelial cancers [67]. The study found that phosphorylation of Akt in cancer can effectively inhibit the expression of Scgb3a1 [68]. Se-Met significantly activated Akt expression in the brain of AD mice [11]. It is speculated that Se-Met might reduce the expression of Scgb3a1 by activating Akt in AD mice.
In summary, we provide comprehensive insights into the transcriptome of 3×Tg-AD mice’s OB tissues. The results showed that upregulated genes mainly regulate the regeneration of nerves, such as Fabp7, Evt5 and Gal; improve cognition and memory, such as Areg; and impact oxidative stress and apoptosis, such as Adcyap1 and Scg2. The downregulated genes are mainly associated with inflammation and apoptosis, such as Lrg1, Scgb3a1 and Pglyrp1. This study is, to the best of our knowledge, the first report of Se-Met-treated OB whole transcriptome sequencing (RNA-Seq). Our results revealed a number of genes implicated in AD pathology and drug metabolism after the treatment with Se-Met. This is in line with previously described effects of Se-Met on AD model mice and provides a theoretical basis for further study of the treatment of AD by Se-Met.

4. Material and Methods

4.1. Transgenic Mice

3×Tg-AD mice (4 months old), purchased from the Jackson Laboratory (Bar Harbor, Maine, ME, USA), were kept with accessible food and water under a 12-h light/dark cycle [69]. All animal experiments and procedures were approved by the Ethics Committee of Shenzhen University (Permit Number: AEWC-20140615-002, 15 July 2014). Mice (n = 6; 6 males and 6 females) were treated with 6 μg/mL Se-Met (Sigma-Aldrich, Santa Clara, CA, USA) in drinking water or received normal drinking water for 3 months.

4.2. Tissue Processing

Mice were euthanized after treatment with Se-Met for 90 days, and the brains were rapidly removed. One hemibrain was washed with PBS in 4 °C, and the olfactory bulb was isolated. Total RNA was extracted from the dissected olfactory bulb by the RNeasy Micro Kit (74004, Qiagen, Beijing, China) according to the manufacturer’s instructions and eluted with 14 mL of RNase-free water. RNA concentrations were determined using NanoDrop 1000 (Thermo Scientific, Shanghai, China). The other hemibrain was snap frozen and stored at −80 °C until further use.

4.3. RNA-Seq Analysis

The following parameters were set for RNA quality control: A260/A280 ratio >1.8, A260/A230 ratio >2.0 and RIN value >7.0. The TruSeq RNA sample preparation kit (Illumina, San Diego, CA, USA) was used for RNA-seq library preparation. Finally, sequencing of the libraries was conducted on an Illumina HiSeqTM 2500 system. A computational pipeline was used to process RNA-seq data. Sequence data were mapped to the mouse reference genome GRCm38 with Tophat v1.4.0 [70] with default parameters. HTSeq-count was subsequently employed to convert aligned short reads into read counts for each gene model in the European Bioinformatics Institute (ENSEMBL) database release [71]. Differential expression was assessed by DEseq using read counts as input [72]. The Benjamini–Hochberg multiple test correction method was enabled. Differentially expressed genes were chosen according to the criteria fold change >2 and adjusted p-value <0.05.

4.4. Differential Expression Analysis

To normalize for GC-content within and between lanes, full-quantile normalization as implemented in the EDASeq R package was performed. Dispersion was estimated with the help of the DESeq R package, treating all samples as replicates of a single condition [73]. Subsequent analyses were based on fitted dispersion values. Two conditions were compared with a negative binomial test. Differential expression was deemed significant if the Benjamini–Hochberg corrected p-value was less than 0.05. Se-Met-treated versus control gene expressions were compared. Overlap in the up- and downregulated genes between the different groups was visualized using BioVenn [74,75].
Functional annotation clustering was performed using the DAVID software tool [76] or OmicsBean (http://www.omicsbean.cn) database. Annotations from Gene Ontology (GO) [77] and Kyoto Encyclopedia of Genes and Genomes (KEGG) [78] were tested for enrichment.

4.5. Real-Time PCR

Ten genes were selected for further real-time PCR analysis, including Adcyap1 (adenylate cyclase activating polypeptide 1), Areg (amphiregulin), Scg2 (secretogranin II), Fabp7 (fatty acid binding protein 7), Etv5 (ets variant 5), Gal (galanin), GAPDH (glyceraldehyde-3-phosphate dehydrogenase), Lrg (leucine-rich alpha-2-glycoprotein 1), Scgb3a1 (secretoglobin, family 3A, member 1), and Pglyrp1(peptidoglycan recognition protein 1).
Complementary DNA was produced from cellular RNA (5 μg) using a Prime Script TM RT reagent Kit (Perfect Real Time) (Takara, Shanghai, China). Real-time PCR primers were designed using PRIMER EXPRESS software (Version 1.5, Applied Biosystems), and the specificity of sequences was verified using BLAST (http://www.ncbi.nlm.nih.gov/BLAST/). Reactions were performed in 10 μL quantities of diluted cDNA sample, primers (100, 200, or 300 nM), and a SYBR Green PCR Master Mix containing nucleotides, AmpliTaq Gold DNA polymerase, and optimized buffer components (Applied Biosystems). Primers were purchased from BGI (Beijing Genomics Institute, Beijing, China) as intron-spanning validated primer pairs. Reactions were assayed using an Applied Biosystems Prism 7700 sequence detection system. After cycling, a melting curve was produced via the slow denaturation of PCR end products to validate amplification specificity. Predicted cycle threshold (CT) values were exported into EXCEL worksheets for analysis. Comparative CT methods were used to determine relative gene expression folds to GAPDH. GAPDH primers were used to confirm gene expression levels. The primers used for real-time PCR were as Table 4:

4.6. Statistical Analysis

The data were analyzed using GraphPad Prism software. All data were expressed as the mean ± SEM and considered statistically significant at a level of p < 0.05. A two-way t-test was used to analyze the QPCR analysis data.

Supplementary Materials

It can be found at https://www.mdpi.com/1422-0067/20/12/2998/s1.

Consent for Publication

The authors showed their consent for publication of the research results.

Ethics Approval and Consent to Participate

All animal experiments and procedures were approved by the Ethics Committee of Shenzhen University (Permit Number: AEWC-20140615-002, 15 July 2014).

Author Contributions

G.L.S., R.Z. and Z.H.Z. conceived and designed the experiments, analyzed the data and drafted the manuscript. Y.X.Z., C.C., S.Z.J. and X.C.C. performed the experiments and helped to revise the manuscript. L.M.S. and J.Z.N. helped to revise the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Sciences Foundation of China (Grants 81400847).

Acknowledgments

We are grateful to Large-scale instrument and equipment public service platform of College of Life and Ocean Sciences for their technical assistance.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Qiu, W.Y.; Yang, Q.; Zhang, W.; Wang, N.; Zhang, D.; Huang, Y.; Ma, C. The correlations between postmortem brain pathologies and cognitive dysfunction in aging and Alzheimer’s disease. Curr. Alzheimer Res. 2017, 15, 462–473. [Google Scholar] [CrossRef] [PubMed]
  2. Libro, R.; Bramanti, P.; Mazzon, E. Endogenous glucocorticoids: Role in the etiopathogenesis of Alzheimer’s disease. Neuro Endocrinol. Lett. 2017, 38, 1–12. [Google Scholar] [PubMed]
  3. Jevtic, S.; Sengar, A.S.; Salter, M.W.; McLaurin, J. The role of the immune system in Alzheimer disease: Etiology and treatment. Ageing Res. Rev. 2017, 40, 84–94. [Google Scholar] [CrossRef] [PubMed]
  4. Rey, N.L.; Wesson, D.W.; Brundin, P. The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. Neurobiol. Dis. 2016, 109, 226–248. [Google Scholar] [CrossRef]
  5. Arnold, S.E.; Lee, E.B.; Moberg, P.J.; Stutzbach, L.; Kazi, H.; Han, L.Y.; Lee, V.M.; Trojanowski, J.Q. Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease. Ann. Neurol. 2010, 67, 462–469. [Google Scholar] [CrossRef]
  6. Xu, Z.P.; Yang, S.L.; Zhao, S.; Zheng, C.H.; Li, H.H.; Zhang, Y.; Huang, R.X.; Li, M.Z.; Gao, Y.; Zhang, S.J.; et al. Biomarkers for early diagnostic of mild cognitive impairment in type-2 diabetes patients: A multicentre, retrospective, nested case-control study. EBioMedicine 2016, 5, 105–113. [Google Scholar] [CrossRef]
  7. Dammalli, M.; Dey, G.; Madugundu, A.K.; Kumar, M.; Rodrigues, B.; Gowda, H.; Siddaiah, B.G.; Mahadevan, A.; Shankar, S.K.; Prasad, T.S.K. Proteomic analysis of the human olfactory bulb. OMICS 2017, 21, 440–453. [Google Scholar] [CrossRef] [PubMed]
  8. Marciniuk, K.; Ryan, T.; Scott, N. Evidence for Prion-Like Mechanisms in Several Neurodegenerative Diseases: Potential Implications for Immunotherapy. Clin. Dev. Immunol. 2013, 2013, 1–20. [Google Scholar] [CrossRef] [Green Version]
  9. Zhang, Z.H.; Wu, Q.Y.; Zheng, R.; Chen, C.; Chen, Y.; Liu, Q.; Hoffmann, P.R.; Ni, J.Z.; Song, G.L. Selenomethionine mitigates cognitive decline by targeting both tau hyperphosphorylation and autophagic clearance in an Alzheimer’s disease mouse model. J. Neurosci. 2017, 37, 2449–2462. [Google Scholar] [CrossRef]
  10. Zhang, Z.H.; Chen, C.; Wu, Q.Y.; Zheng, R.; Chen, Y.; Liu, Q.; Ni, J.Z.; Song, G.L. Selenomethionine ameliorates neuropathology in the olfactory bulb of a triple transgenic mouse model of Alzheimer’s disease. Int. J. Mol. Sci. 2016, 17, 1595. [Google Scholar] [CrossRef]
  11. Zhang, Z.H.; Wu, Q.Y.; Chen, C.; Zheng, R.; Chen, Y.; Ni, J.Z.; Song, G.L. Comparison of the effects of selenomethionine and selenium-enriched yeast in the triple-transgenic mouse model of Alzheimer’s disease. Food Funct. 2018, 9, 3965–3973. [Google Scholar] [CrossRef]
  12. Zheng, R.; Zhang, Z.H.; Chen, C.; Chen, Y.; Jia, S.Z.; Liu, Q.; Ni, J.Z.; Song, G.L. Selenomethionine promoted hippocampal neurogenesis via the PI3K-Akt-GSK3beta-Wnt pathway in a mouse model of Alzheimer’s disease. Biochem. Biophys. Res. Commun. 2017, 485, 6–15. [Google Scholar] [CrossRef]
  13. Zhang, Z.H.; Chen, C.; Wu, Q.Y.; Zheng, R.; Liu, Q.; Ni, J.Z.; Hoffmann, P.R.; Song, G.L. Selenomethionine reduces the deposition of beta-amyloid plaques by modulating beta-secretase and enhancing selenoenzymatic activity in a mouse model of Alzheimer’s disease. Metallomics 2016, 8, 782–789. [Google Scholar] [CrossRef] [PubMed]
  14. Theodore, J.A. A Framework for Comparative Analysis of Gene Expressions and Mutations Linked to Cancer. Ph.D. Thesis, The George Washington University, Washington, DC, USA, 2014. [Google Scholar]
  15. Van Dijck, A.; Vloeberghs, E.; Van Dam, D.; Staufenbiel, M.; De Deyn, P.P. Evaluation of the APP23-model for Alzheimer’s disease in the odour paired-associate test for hippocampus-dependent memory. Behav. Brain Res. 2008, 190, 147–151. [Google Scholar] [CrossRef] [PubMed]
  16. Hipp, G.; Diederich, N.J.; Pieria, V.; Vaillant, M. Primary vision and facial emotion recognition in early Parkinson’s disease. J. Neurol. Sci. 2014, 338, 178–182. [Google Scholar] [CrossRef]
  17. Suto, T.; Meguro, K.; Nakatsuka, M.; Kato, Y.; Tezuka, K.; Yamaguchi, S.; Tashiro, M. Disorders of “taste cognition” are associated with insular involvement in patients with Alzheimer’s disease and vascular dementia: “Memory of food is impaired in dementia and responsible for poor diet”. Int. Psychogeriatr. 2014, 26, 1127–1138. [Google Scholar] [CrossRef]
  18. Vicente Miranda, H.; El-Agnaf, O.M.A.; Outeiro, T.F. Glycation in Parkinson’s disease and Alzheimer’s disease. Mov. Disord. 2016, 31, 782–790. [Google Scholar] [CrossRef]
  19. Pintana, H.; Apaijai, N.; Kerdphoo, S.; Pratchayasakul, W.; Sripetchwandee, J.; Suntornsaratoon, P.; Charoenphandhu, N.; Chattipakorn, N.; Chattipakorn, S.C. Hyperglycemia induced the Alzheimer’s proteins and promoted loss of synaptic proteins in advanced-age female Goto-Kakizaki (GK) rats. Neurosci. Lett. 2017, 655, 41. [Google Scholar] [CrossRef] [PubMed]
  20. Bakir, B.; Sanli, S.; Bakir, V.L.; Ayas, S.; Yildiz, S.O.; Iyibozkurt, A.C.; Kartal, M.G.; Yavuz, E. Role of diffusion weighted MRI in the differential diagnosis of endometrial cancer, polyp, hyperplasia, and physiological thickening. Clin. Imaging 2017, 41, 86–94. [Google Scholar] [CrossRef] [PubMed]
  21. Arrieta-Cruz, I.; Gutiérrez-Juárez, R. The role of insulin resistance and glucose metabolism dysregulation in the development of Alzheimer´s disease. Revista Investig. Clin. 2016, 68, 53–58. [Google Scholar]
  22. Tang, Y.; Soroush, F.; Sun, S.; Liverani, E.; Langston, J.C.; Yang, Q.; Kilpatrick, L.E.; Kiani, M.F. Protein kinase C-delta inhibition protects blood-brain barrier from sepsis-induced vascular damage. J. Neuroinflamm. 2018, 15, 309. [Google Scholar] [CrossRef]
  23. Bennett, C.; Mohammed, F.; Álvarez-Ciara, A.; Nguyen, M.A.; Dietrich, W.D.; Rajguru, S.M.; Streit, W.J.; Prasad, A. Neuroinflammation, oxidative stress, and blood-brain barrier (BBB) disruption in acute Utah electrode array implants and the effect of deferoxamine as an iron chelator on acute foreign body response. Biomaterials 2018, 188, 144–159. [Google Scholar] [CrossRef]
  24. Martens, E.J.; Hoen, P.W.; Mittelhaeuser, M.; De Jonge, P.; Denollet, J. Symptom dimensions of post-myocardial infarction depression, disease severity and cardiac prognosis. Psychol. Med. 2010, 40, 807. [Google Scholar] [CrossRef]
  25. Nieweg, K.; Schaller, H.F. Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J. Neurochem. 2010, 109, 125–134. [Google Scholar] [CrossRef]
  26. Vance, J.E.; Pan, D.; Campenot, R.B.; Bussière, M.; Vance, D.E. Evidence that the major membrane lipids, except cholesterol, are made in axons of cultured rat sympathetic neurons. J. Neurochem. 2010, 62, 329–337. [Google Scholar] [CrossRef]
  27. Stocker, H.; Mollers, T.; Perna, L.; Brenner, H. The genetic risk of Alzheimer’s disease beyond APOE epsilon4: Systematic review of Alzheimer’s genetic risk scores. Transl. Psychiatr. 2018, 8, 166. [Google Scholar] [CrossRef]
  28. Kim, Y.; Kim, C.; Jang, H.Y.; Mook-Jung, I. Inhibition of cholesterol biosynthesis reduces γ-secretase activity and amyloid-î² generation. J. Alzheimers Dis. 2016, 51, 1057–1068. [Google Scholar] [CrossRef]
  29. Wang, C.; Shou, Y.; Pan, J.; Du, Y.; Liu, C.; Wang, H. The relationship between cholesterol level and Alzheimer’s disease-associated APP proteolysis/Aβ metabolism. Nutr. Neurosci. 2018, 22, 1–11. [Google Scholar] [CrossRef]
  30. Hui, L.; Chen, X.; Geiger, J.D. Endolysosome involvement in LDL cholesterol-induced Alzheimer’s disease-like pathology in primary cultured neurons. Life Sci. 2012, 91, 1159–1168. [Google Scholar] [CrossRef]
  31. Sawamura, N.; Gong, J.S.; Chang, T.Y.; Yanagisawa, K.; Michikawa, M. Promotion of tau phosphorylation by MAP kinase Erk1/2 is accompanied by reduced cholesterol level in detergent-insoluble membrane fraction in Niemann-Pick C1-deficient cells. J. Neurochem. 2010, 84, 1086–1096. [Google Scholar] [CrossRef]
  32. Eunjeong, Y.; Sangzin, A.; Junghwa, R.; Moonseok, C.; Shinkyu, C.; Young, H.C.; Jinwon, H.; Moonjeong, C.; Hyesun, K. The reduced protein level of synaptophysin and PSD-95 was restored by phloroglucinol in 5XFAD Tg mouse model. PLoS ONE 2015, 10, 8–22. [Google Scholar]
  33. Han, P.; Caselli, R.J.; Baxter, L.; Serrano, G.; Yin, J.; Beach, T.G.; Reiman, E.M.; Shi, J. Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease. JAMA Neurol. 2015, 72, 333–339. [Google Scholar] [CrossRef]
  34. Hashimoto, R.; Hashimoto, H.; Shintani, N.; Ohi, K.; Hori, H.; Saitoh, O.; Kosuga, A.; Tatsumi, M.; Iwata, N.; Ozaki, N.; et al. Possible association between the pituitary adenylate cyclase-activating polypeptide (PACAP) gene and major depressive disorder. Neurosci. Lett. 2010, 468, 300–302. [Google Scholar] [CrossRef]
  35. Rat, D.; Schmitt, U.; Tippmann, F.; Dewachter, I.; Theunis, C.; Wieczerzak, E.; Postina, R.; Van Leuven, F.; Fahrenholz, F.; Kojro, E. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer’s disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 2011, 25, 3208–3218. [Google Scholar] [CrossRef]
  36. Reglodi, D.; Kiss, P.; Lubics, A.; Tamas, A. Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr. Pharm Des. 2011, 17, 962–972. [Google Scholar] [CrossRef]
  37. Shieh, P.C.; Tsao, C.W.; Li, J.S.; Wu, H.T.; Wen, Y.J.; Kou, D.H.; Cheng, J.T. Role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the action of ginsenoside Rh2 against beta-amyloid-induced inhibition of rat brain astrocytes. Neurosci. Lett. 2008, 434, 1–5. [Google Scholar] [CrossRef]
  38. Mao, S.S.; Zhang, Y.M. Research advance of the protective role of PACAP in the nervous system diseases. Sheng Li Ke Xue Jin Zhan Progr. 2011, 42, 276–280. [Google Scholar]
  39. Koster, K.P.; Thomas, R.; Morris, A.W.; Tai, L.M. Epidermal growth factor prevents oligomeric amyloid-beta induced angiogenesis deficits in vitro. J. Cereb. Blood Flow Metab. 2016, 36, 1865–1871. [Google Scholar] [CrossRef]
  40. Thomas, R.; Zuchowska, P.; Morris, A.W.; Marottoli, F.M.; Sunny, S.; Deaton, R.; Gann, P.H.; Tai, L.M. Epidermal growth factor prevents APOE4 and amyloid-beta-induced cognitive and cerebrovascular deficits in female mice. Acta Neuropathol. Commun. 2016, 4, 111. [Google Scholar] [CrossRef] [Green Version]
  41. Li, T.; Wen, H.; Brayton, C.; Das, P.; Smithson, L.A.; Fauq, A.; Fan, X.; Crain, B.J.; Price, D.L.; Golde, T.E.; et al. Epidermal growth factor receptor and notch pathways participate in the tumor suppressor function of gamma-secretase. J. Biol. Chem. 2007, 282, 32264–32273. [Google Scholar] [CrossRef]
  42. Lachen-Montes, M.; Zelaya, M.V.; Segura, V.; Fernandez-Irigoyen, J.; Santamaria, E. Progressive modulation of the human olfactory bulb transcriptome during Alzheimer’s disease evolution: Novel insights into the olfactory signaling across proteinopathies. Oncotarget 2017, 8, 69663–69679. [Google Scholar] [CrossRef]
  43. Guillemot, J.; Thouennon, E.; Guerin, M.; Vallet-Erdtmann, V.; Ravni, A.; Montero-Hadjadje, M.; Lefebvre, H.; Klein, M.; Muresan, M.; Seidah, N.; et al. Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: Implications for the production of the tumoral marker EM66. J. Mol. Endocrinol. 2012, 48, 115–127. [Google Scholar] [CrossRef]
  44. Willis, M.; Prokesch, M.; Hutter-Paier, B.; Windisch, M.; Stridsberg, M.; Mahata, S.K.; Kirchmair, R.; Wietzorrek, G.; Knaus, H.G.; Jellinger, K.; et al. Chromogranin B and Secretogranin II in transgenic mice overexpressing human APP751 with the London (V717I) and Swedish (K670M/N671L) mutations and in Alzheimer patients. J. Alzheimers Dis. 2008, 13, 123–135. [Google Scholar] [CrossRef]
  45. Hart, J.E.; Clarke, I.J.; Risbridger, G.P.; Ferneyhough, B.; Vega-Hernandez, M. Mysterious inhibitory cell regulator investigated and found likely to be secretogranin II related. PeerJ 2017, 5, e3833. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Fischer-Colbrie, R.; Kirchmair, R.; Kahler, C.M.; Wiedermann, C.J.; Saria, A. Secretoneurin: A new player in angiogenesis and chemotaxis linking nerves, blood vessels and the immune system. Curr. Protein Pept. Sci. 2005, 6, 373–385. [Google Scholar] [CrossRef]
  47. Venditti, P.; Masullo, P.; Di Meo, S.; Agnisola, C. Effects of prolonged aerobic exercise on myocardial responses to ischaemia-reperfusion in the rat. Exp. Physiol. 2001, 86, 341–348. [Google Scholar] [CrossRef]
  48. Vo, T.; Wang, S.; Poon, G.M.K.; Wilson, W.D. Electrostatic control of DNA intersegmental translocation by the ETS transcription factor ETV6. J. Biol. Chem. 2017, 292, 13187–13196. [Google Scholar] [CrossRef] [Green Version]
  49. Van Pham, P.; Vu, N.B.; Nguyen, H.T.; Dao, T.T.T.; Le, H.T.N.; Phi, L.T.; Nguyen, O.T.K.; Phan, N.K. ETV-2 activated proliferation of endothelial cells and attenuated acute hindlimb ischemia in mice. Vitro Cell Dev. Biol. Anim. 2017, 53, 616–625. [Google Scholar] [CrossRef]
  50. Young, J.K.; Heinbockel, T.; Gondre-Lewis, M.C. Astrocyte fatty acid binding protein-7 is a marker for neurogenic niches in the rat hippocampus. Hippocampus 2013, 23, 1476–1483. [Google Scholar] [CrossRef] [Green Version]
  51. Matsumata, M.; Inada, H.; Osumi, N. Fatty acid binding proteins and the nervous system: Their impact on mental conditions. Neurosci. Res. 2016, 102, 47–55. [Google Scholar] [CrossRef] [Green Version]
  52. Teunissen, C.E.; Veerhuis, R.; De Vente, J.; Verhey, F.R.J.; Vreeling, F.; van Boxtel, M.P.J.; Glatz, J.F.C.; Pelsers, M.A.L. Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases. Eur. J. Neurol. 2011, 18, 865–871. [Google Scholar] [CrossRef] [PubMed]
  53. Hoeijmakers, L.; Meerhoff, G.F.; de Vries, J.W.; Ruigrok, S.R.; van Dam, A.M.; van Leuven, F.; Korosi, A.; Lucassen, P.J. The age-related slow increase in amyloid pathology in APP.V717I mice activates microglia, but does not alter hippocampal neurogenesis. Neurobiol. Aging 2017, 61, 112–123. [Google Scholar] [CrossRef] [PubMed]
  54. Horgusluoglu-Moloch, E.; Nho, K.; Risacher, S.L.; Kim, S.; Foroud, T.; Shaw, L.M.; Trojanowski, J.Q.; Aisen, P.S.; Petersen, R.C.; Jack, C.R., Jr.; et al. Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer’s disease. Neurobiol. Aging 2017, 60, 92–103. [Google Scholar] [CrossRef] [PubMed]
  55. Beart, P.M. Synaptic signalling and its interface with neuropathologies: Snapshots from the past, present and future. J. Neurochem. 2016, 139 (Suppl. 2), 76–90. [Google Scholar] [CrossRef]
  56. Ádori, C.; Glück, L.; Barde, S.; Yoshitake, T.; Kovacs, G.G.; Mulder, J.; Maglóczky, Z.; Havas, L.; Bölcskei, K.; Mitsios, N.; et al. Critical role of somatostatin receptor 2 in the vulnerability of the central noradrenergic system: New aspects on Alzheimer’s disease. Acta Neuropathol. 2015, 129, 541–563. [Google Scholar] [CrossRef] [PubMed]
  57. Counts, S.E.; Perez, S.E.; Ginsberg, S.D.; Mufson, E.J. Neuroprotective role for galanin in Alzheimer’s disease. EXS 2010, 102, 143–162. [Google Scholar] [PubMed]
  58. Baraka, A.; ElGhotny, S. Study of the effect of inhibiting galanin in Alzheimer’s disease induced in rats. Eur. J. Pharmacol. 2010, 641, 123–127. [Google Scholar] [CrossRef]
  59. Manuel, I.; Lombardero, L.; LaFerla, F.M.; Gimenez-Llort, L.; Rodriguez-Puertas, R. Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer’s disease. Neuroscience 2016, 329, 284–293. [Google Scholar] [CrossRef]
  60. Nakajima, M.; Miyajima, M.; Ogino, I.; Watanabe, M.; Miyata, H.; Karagiozov, K.L.; Arai, H.; Hagiwara, Y.; Segawa, T.; Kobayashi, K.; et al. Leucine-rich alpha-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus. Acta Neurochir Wien 2011, 153, 1339–1346; discussion 46. [Google Scholar] [CrossRef]
  61. Jingami, N.; Asada-Utsugi, M.; Uemura, K.; Noto, R.; Takahashi, M.; Ozaki, A.; Kihara, T.; Kageyama, T.; Takahashi, R.; Shimohama, S.; et al. Idiopathic normal pressure hydrocephalus has a different cerebrospinal fluid biomarker profile from Alzheimer’s disease. J. Alzheimers Dis. 2015, 45, 109–115. [Google Scholar] [CrossRef]
  62. Pek, S.L.T.; Cheng, A.K.S.; Lin, M.X.; Wong, M.S.; Chan, E.Z.L.; Moh, A.M.C.; Sum, C.F.; Lim, S.C.; Tavintharan, S. Association of circulating proinflammatory marker, leucine-rich-alpha2-glycoprotein (LRG1), following metabolic/bariatric surgery. Diabetes Metab. Res. Rev. 2018, 34, e3029. [Google Scholar] [CrossRef] [PubMed]
  63. Read, C.B.; Kuijper, J.L.; Hjorth, S.A.; Heipel, M.D.; Tang, X.; Fleetwood, A.J.; Dantzler, J.L.; Grell, S.N.; Kastrup, J.; Wang, C.; et al. Cutting Edge: Identification of neutrophil PGLYRP1 as a ligand for TREM-1. J. Immunol. 2015, 194, 1417–1421. [Google Scholar] [CrossRef]
  64. Yin, S.J.; Cho, I.H.; Yang, H.S.; Park, Y.D.; Yang, J.M. Analysis of the peptides detected in atopic dermatitis and various inflammatory diseases patients-derived sera. Int. J. Biol. Macromol. 2017, 106, 1052–1061. [Google Scholar] [CrossRef]
  65. Kim, S.K.; Seok, H.; Park, H.J.; Han, K.; Kang, S.W.; Ban, J.Y.; Jung, H.J.; Kim, K.I.; Lee, B.J.; Kim, J.; et al. Association between secretoglobin family 3A member 2 (SCGB3A2) gene polymorphisms and asthma in a Korean population. Med. Sci. Monit. 2017, 23, 1880–1885. [Google Scholar] [CrossRef]
  66. Tokuda, T.; Tanaka, K.; Kametani, F.; Ikeda, S.; Yanagisawa, N. Secretory form of beta-amyloid precursor protein is much abundantly contained in the cerebral white matter in human brain. Neurosci. Lett. 1994, 175, 33–36. [Google Scholar] [CrossRef]
  67. Haakensen, V.D.; Bjøro, T.; Lüders, T.; Riis, M.; Bukholm, I.K.; Kristensen, V.N.; Troester, M.A.; Homen, M.M.; Ursin, G.; Børresen-Dale, A.L.; et al. Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas. BMC Cancer 2011, 11, 332. [Google Scholar] [CrossRef] [PubMed]
  68. Danielsen, S.; Lind, G.; Berg, E.V.D.; Kolberg, M.; Mertens, F.; Lothe, R. RASSF1A and SCGB3A1 are common target genes for promoter hypermethylation in malignant peripheral nerve sheath tumors. Cancer Res. 2007, 67, 2875. [Google Scholar]
  69. Oddo, S.; Caccamo, A.; Kitazawa, M.; Tseng, B.P.; LaFerla, F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol. Aging 2003, 24, 1063–1070. [Google Scholar] [CrossRef] [PubMed]
  70. Trapnell, C.; Pachter, L.; Salzberg, S.L. TopHat: Discovering splice junctions with RNA-Seq. Bioinformatics 2009, 25, 1105–1111. [Google Scholar] [CrossRef] [PubMed]
  71. Anders, S.; Huber, W. Differential expression analysis for sequence count data. Genome Biol. 2010, 11, R106. [Google Scholar] [CrossRef]
  72. Huang, D.W.; Sherman, B.T.; Tan, Q.; Kir, J.; Liu, D.; Bryant, D.; Guo, Y.; Stephens, R.; Baseler, M.W.; Lane, H.C.; et al. DAVID bioinformatics resources: Expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 2007, 35, W169–W175. [Google Scholar] [CrossRef]
  73. Huttenrauch, M.; Baches, S.; Gerth, J.; Bayer, T.A.; Weggen, S.; Wirths, O. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer’s disease. J. Alzheimers Dis. 2015, 44, 1291–1302. [Google Scholar] [CrossRef] [PubMed]
  74. Huang da, W.; Sherman, B.T.; Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4, 44–57. [Google Scholar] [CrossRef] [PubMed]
  75. Havugimana, P.C.; Hu, P.; Emili, A. Protein complexes, big data, machine learning and integrative proteomics: Lessons learned over a decade of systematic analysis of protein interaction networks. Expert Rev. Proteom. 2017, 14, 845–855. [Google Scholar] [CrossRef] [PubMed]
  76. Wirths, O.; Breyhan, H.; Marcello, A.; Cotel, M.C.; Bruck, W.; Bayer, T.A. Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP/PS1KI mouse model of Alzheimer’s disease. Neurobiol. Aging 2010, 31, 747–757. [Google Scholar] [CrossRef]
  77. Botstein, D.; Cherry, J.M.; Ashburner, M.; Ball, C.A.; Blake, J.A.; Butler, H.; Davis, A.P.; Dolinski, K.; Dwight, S.S.; Eppig, J.T. Gene ontology: Tool for the unification of biology. Nat. Genet. 2000, 25, 25–29. [Google Scholar]
  78. Faure, A.; Verret, L.; Bozon, B.; El Tayara, N.E.T.; Ly, M.; Kober, F.; Dhenain, M.; Rampon, C.; Delatour, B. Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer’s disease. Neurobiol. Aging 2011, 32, 407–418. [Google Scholar] [CrossRef]
Ijms 20 02998 g001 550
Figure 1. Volcano plots of significantly differentially expressed genes. log FC (fold-change) (X-axis) and p-value (Y-axis) of differentially expressed genes (DEGs) comparing control versus Se-Met-treated 3×Tg-AD mice. Each dot represents a single DEG, and a red dot illustrates statistical significance (p = 0.05). Left-downregulated; Right–upregulated.
Figure 1. Volcano plots of significantly differentially expressed genes. log FC (fold-change) (X-axis) and p-value (Y-axis) of differentially expressed genes (DEGs) comparing control versus Se-Met-treated 3×Tg-AD mice. Each dot represents a single DEG, and a red dot illustrates statistical significance (p = 0.05). Left-downregulated; Right–upregulated.
Ijms 20 02998 g001
Ijms 20 02998 g002 550
Figure 2. KEGG Pathway names for DEGs. Based on the KEGG biology pathway database (http://www.genome.jp/) from the perspective of complex regulatory networks, the differential gene sets were enriched, thus the most relevant biological pathways on the differentially expressed gene were extracted.
Figure 2. KEGG Pathway names for DEGs. Based on the KEGG biology pathway database (http://www.genome.jp/) from the perspective of complex regulatory networks, the differential gene sets were enriched, thus the most relevant biological pathways on the differentially expressed gene were extracted.
Ijms 20 02998 g002
Ijms 20 02998 g003 550
Figure 3. Gene Ontology identifiers in the cluster of overlapping differentially expressed top 20 genes upregulated in 3xTg AD mice (Se-Met-treated) compared to 3×Tg AD mice.
Figure 3. Gene Ontology identifiers in the cluster of overlapping differentially expressed top 20 genes upregulated in 3xTg AD mice (Se-Met-treated) compared to 3×Tg AD mice.
Ijms 20 02998 g003
Ijms 20 02998 g004 550
Figure 4. Gene Ontology identifiers in the cluster of overlapping differentially expressed top 20 genes downregulated in 3×Tg-AD mice (Se-Met-treated) compared to 3×Tg-AD mice.
Figure 4. Gene Ontology identifiers in the cluster of overlapping differentially expressed top 20 genes downregulated in 3×Tg-AD mice (Se-Met-treated) compared to 3×Tg-AD mice.
Ijms 20 02998 g004
Ijms 20 02998 g005 550
Figure 5. Validation of sequencing results for upregulated (A) or downregulated genes (B) using qRT-PCR. The housekeeping gene GAPDH was used for normalization. Significantly differential expression is indicated as *** p < 0.001; ** p < 0.01; * p < 0.05.
Figure 5. Validation of sequencing results for upregulated (A) or downregulated genes (B) using qRT-PCR. The housekeeping gene GAPDH was used for normalization. Significantly differential expression is indicated as *** p < 0.001; ** p < 0.01; * p < 0.05.
Ijms 20 02998 g005
Table
Table 1. A list of the Gene Ontology identifiers in the cluster of overlapping differentially expressed genes in Se-Met-treated AD mice compared to control AD mice.
Table 1. A list of the Gene Ontology identifiers in the cluster of overlapping differentially expressed genes in Se-Met-treated AD mice compared to control AD mice.
CategoryGO ClassFunctionSample NumberBackground Numberp ValueGene Names
BPGO:0052697xenobiotic glucuronidation452.44 × 10−7Ugt1a2; Ugt1a1; Ugt1a10; Ugt1a6a
BPGO:0052696flavonoid glucuronidation491.36 × 10−6Ugt1a2; Ugt1a1; Ugt1a10; Ugt1a6a
BPGO:0009813flavonoid biosynthetic process491.36 × 10−6Ugt1a2; Ugt1a1; Ugt1a10; Ugt1a6a
BPGO:0052695cellular glucuronidation4101.89 × 10−6Ugt1a2; Ugt1a1; Ugt1a10; Ugt1a6a
BPGO:0019585glucuronate metabolic process4112.56 × 10−6Ugt1a2; Ugt1a1; Ugt1a10; Ugt1a6a
BPGO:0006063uronic acid metabolic process4112.56 × 10−6Ugt1a2; Ugt1a1; Ugt1a10; Ugt1a6a
BPGO:0009812flavonoid metabolic process4112.56 × 10−6Ugt1a2; Ugt1a1; Ugt1a10; Ugt1a6a
BPGO:0006805xenobiotic metabolic process5544.93 × 10−5Ugt1a2; Ugt1a1; Cyp2f2; Ugt1a10; Ugt1a6a
BPGO:0071466cellular response to xenobiotic stimulus5586.77 × 10−5Ugt1a2; Ugt1a1; Cyp2f2; Ugt1a10; Ugt1a6a
BPGO:0009410response to xenobiotic stimulus5641.04 × 10−4Ugt1a2; Ugt1a1; Cyp2f2; Ugt1a10; Ugt1a6a
CCGO:0005615extracellular space2510117.36 × 10−8Pigr; Adcyap1; Tacstd2; Fetub; Pglyrp1; Gpx3;
Sftpd; Dmbt1; Pon1; Ces1d; Lbp; Scgb3a1; Mup4;
C1s; Bpifb1; Areg; Msln; Anxa1; Tnfsf15;
Serpinb11; Bpifa1; Nppa; Il1r1; Scg2; St14
CCGO:0005576extracellular region5235936.55 × 10−5Pigr; Reg3g; Bpifa1; Tspan1; Tacstd2; Krt14; Ccdc3;
Vwf; Fetub; Pglyrp1; Gpx3; Scnn1a; Krt5; Sftpd;
Dmbt1; Ces1d; Pon1; Agr2; Obp2a; Cd44; Sult1c1;
Lbp; Chi3l4; Scgb3a1; Mup4; Wfdc18; C1s; Gsta3;
Muc20; Il1r1; Bpifb1; Krt18; Areg; Wfdc2; Msln;
Lypd2; Anxa1; Tnfsf15; Epcam; Serpinb11; Steap4;
Slc5a9; Cd177; Clic6; Adcyap1; Ugt1a6a; St14;
Tmprss2; Slc44a4; Slc39a4; Scg2; Nppa
CCGO:0044421extracellular region part4430715.7 × 10−6Pigr; Adcyap1; Tspan1; Tacstd2; Krt14; Vwf; Fetub;
Pglyrp1; Gpx3; Scnn1a; Krt5; Sftpd; Dmbt1; Ces1d;
Pon1; Cd44; Sult1c1; Lbp; Scgb3a1; Mup4; C1s;
Gsta3; Il1r1; Bpifb1; Krt18; Areg; Wfdc2; Msln;
Anxa1; Tnfsf15; Epcam; Serpinb11; Steap4; Slc5a9; Cd177; Clic6; Bpifa1; Ugt1a6a; St14; Tmprss2;
Slc44a4; Slc39a4; Scg2; Nppa
CCGO:0016323basolateral plasma membrane81763.91 × 10−5Tacstd2; Cd44; St14; Cldn8; Epcam; Cldn7; Muc20; Aqp3
CCGO:0070062extracellular vesicular exosome3222801.4 × 10−4Pigr; Pglyrp1; Tspan1; Tacstd2; Krt14; Gsta3; Fetub;
Scnn1a; Krt5; Dmbt1; Pon1; Cd44; Sult1c1; Lbp;
Scgb3a1; Gpx3; C1s; Vwf; Bpifb1; Krt18; Wfdc2;
Anxa1; Epcam; Steap4; Slc5a9; Cd177; Clic6;
Ugt1a6a; Tmprss2; Slc44a4; Slc39a4; St14
CCGO:1903561extracellular vesicle3222801.41 × 10−4Pigr; Pglyrp1; Tspan1; Tacstd2; Krt14; Gsta3; Fetub; Scnn1a; Krt5; Dmbt1; Pon1; Cd44; Sult1c1; Lbp;
Scgb3a1; Gpx3; C1s; Vwf; Bpifb1; Krt18; Wfdc2;
Anxa1; Epcam; Steap4; Slc5a9; Cd177; Clic6;
Ugt1a6a; Tmprss2; Slc44a4; Slc39a4; St14
CCGO:0043230extracellular organelle3222841.44 × 10−4Pigr; Pglyrp1; Tspan1; Tacstd2; Krt14; Gsta3; Fetub; Scnn1a; Krt5; Dmbt1; Pon1; Cd44; Sult1c1; Lbp;
Scgb3a1; Gpx3; C1s; Vwf; Bpifb1; Krt18; Wfdc2;
Anxa1; Epcam; Steap4; Slc5a9; Cd177; Clic6;
Ugt1a6a; Tmprss2; Slc44a4; Slc39a4; St14
CCGO:0065010extracellular membrane-bounded organelle3222841.45 × 10−4Pigr; Pglyrp1; Tspan1; Tacstd2; Krt14; Gsta3; Fetub; Scnn1a; Krt5; Dmbt1; Pon1; Cd44; Sult1c1; Lbp;
Scgb3a1; Gpx3; C1s; Vwf; Bpifb1; Krt18; Wfdc2;
Anxa1; Epcam; Steap4; Slc5a9; Cd177; Clic6;
Ugt1a6a; Tmprss2; Slc44a4; Slc39a4; St14
CCGO:0031988membrane-bounded vesicle3527564.34 × 10−4Pigr; Pglyrp1; Tspan1; Tacstd2; Krt14; Th; Gsta3;
Fetub; Gpx3; Scnn1a; Krt5; Dmbt1; Pon1; Cd44;
Sult1c1; Lbp; Scgb3a1; Scg2; C1s; Vwf; Bpifb1;
Krt18; Wfdc2; Galnt15; Anxa1; Epcam; Steap4;
Slc5a9; Cd177; Clic6; Ugt1a6a; Tmprss2; Slc44a4;
Slc39a4; St14
CCGO:0098590plasma membrane region104288.69 × 10−4Aqp3; Cd44; St14; Cldn8; Slc39a4; Scnn1a; Epcam; Cldn7; Muc20; Tacstd2
MFGO:0015020glucuronosyltransferase activity5741.99 × 10−4Ugt1a2; Ugt1a1; Galnt15; Ugt1a6a; Ugt1a10
MFGO:0008194UDP-glycosyltransferase activity61354.03 × 10−4Ugt1a2; Galnt15; Ugt1a1; Ugt1a6a; Gal; Ugt1a10
MFGO:0016758transferase activity, transferring hexosyl groups61651.11 × 10−4Ugt1a2; Galnt15; Ugt1a1; Ugt1a6a; Gal; Ugt1a10
MFGO:0005154epidermal growth factor receptor binding3301.4 × 10−3Pigr; Cd44; Areg
MFGO:0016757transferase activity, transferring glycosyl groups72431.62 × 10−3St6galnac1; Ugt1a2; Galnt15; Ugt1a1; Ugt1a6a; Gal; Ugt1a10
MFGO:0001972retinoic acid binding2123.85 × 10−3Ugt1a2; Ugt1a1
MFGO:0019865immunoglobulin binding2145.03 × 10−3Vwf; Fcamr
MFGO:0038024cargo receptor activity3536.34 × 10−3Ildr1; Tmprss2; Dmbt1
MFGO:0051428peptide hormone receptor binding2166.36 × 10−3Adcyap1; Nppa
MFGO:0033293monocarboxylic acid binding3556.9 × 10−3Ugt1a2; Ugt1a1; Fabp7
BP, biological process; CC, cellular component; MF, molecular function.
Table
Table 2. 20 genes upregulated in Se-Met-treated 3×Tg-AD mice versus 3×Tg-AD mice.
Table 2. 20 genes upregulated in Se-Met-treated 3×Tg-AD mice versus 3×Tg-AD mice.
Gene NameGene DescriptionlogFCp_Value
Adcyap1adenylate cyclase activating polypeptide 11.496.74 × 10−12
Aregamphiregulin3.491.46 × 10−9
Scg2secretogranin II1.021.51 × 10−7
Thtyrosine hydroxylase1.312.8 × 10−7
Fabp7fatty acid binding protein 71.296.41 × 10−7
Pip5k1bphosphatidylinositol-4-phosphate 5-kinase,
type 1 beta		1.034.68 × 10−6
Trhr2thyrotropin releasing hormone receptor 21.695.55 × 10−6
Etv5ets variant 51.025.68 × 10−5
fantom3_1110005E01///1.011.25 × 10−5
Col28a1collagen, type XXVIII, alpha 11.331.59 × 10−5
fantom3_D930027K06///1.771.73 × 10−5
fantom3_D930001D16///1.771.73 × 10−5
Gm10635predicted gene 106352.912.09 × 10−5
Nppanatriuretic peptide type A1.202.18 × 10−5
Nt5c1a5′-nucleotidase, cytosolic IA1.368.67 × 10−5
Galgalanin1.489.23 × 10−5
fantom3_A430024L20///1.129.76 × 10−5
Rxfp1relaxin/insulin-like family peptide receptor 11.731.18 × 10−4
fantom3_C330006P03///1.121.25 × 10−4
Tnfsf15tumor necrosis factor (ligand) superfamily, member 152.761.33 × 10−4
Note: “///” indicates that there is currently no relevant research.
Table
Table 3. Top 20 genes downregulated in Se-Met-treated 3×Tg-AD mice versus 3×Tg-AD mice.
Table 3. Top 20 genes downregulated in Se-Met-treated 3×Tg-AD mice versus 3×Tg-AD mice.
Gene NameGene DescriptionlogFCp_Value
Lrg1leucine-rich alpha-2-glycoprotein 1−3.082.99 × 10−11
Anxa1annexin A1−2.518.52 × 10−11
Cd177CD177 antigen−3.578.66 × 10−11
VwfVon Willebrand factor−1.152.21 × 10−10
Il1r1interleukin 1 receptor, type I−1.261.35 × 10−9
Scgb3a1secretoglobin, family 3A, member 1−3.757.5 × 10−8
fantom3_1110030K16///−3.911.42 × 10−7
Abca13ATP-binding cassette, sub-family A (ABC1), member 13−4.742.4 × 10−7
Pglyrp1peptidoglycan recognition protein 1−1.613.23 × 10−7
Bpifb1BPI fold containing family B, member 1−6.704.13 × 10−7
Gpx3glutathione peroxidase 3−1.905.13 × 10−7
Dlk1delta-like 1 homolog (Drosophila)−2.515.23 × 10−7
Gabrpgamma-aminobutyric acid (GABA) A receptor, pi−6.285.51 × 10−7
Serpina3nserine (or cysteine) peptidase inhibitor, clade A, member 3N−1.206.65 × 10−7
S100a11S100 calcium binding protein A11−1.287.58 × 10−7
Muc5bmucin 5, subtype B, tracheobronchial−6.357.95 × 10−7
Lypd2Ly6/Plaur domain containing 2−5.618.2 × 10−7
Pon1paraoxonase 1−7.079.8 × 10−7
Il18r1interleukin 18 receptor 1−2.441.79 × 10−6
Ccdc3coiled-coil domain containing 3−1.412.03 × 10−6
Note: “///” indicates that there is currently no relevant research.
Table
Table 4. Primers sequences information.
Table 4. Primers sequences information.
Genes NameSequence Information
Adcyap1Forward5′-GGAGAAAAGTGGAGGGAGCA-3′
Reverse5′-TGTCTATACCTTTTCCCAAGGACTG-3′
AregForward5′-TGGATTGGACCTCAATGACA-3′
Reverse5′-AGCCAGGTATTTGTGGTTCG-3′
Scg2Forward5′-CCAATGGTCATGGTATTGACA-3′
Reverse5′-TTTGCTCCAGAACTCCACAA-3′
Fabp7Forward5′-AGGCTTTCTGTGCTAC-3′
Reverse5′-ATTACCGTTGGTTTGG-3′
Evt5Forward5′-GAAGTGCCTAACTGCCAGTCACCC-3′
Reverse5′-GGCACCACGCAAGTGTCATCGA-3′
GalForward5′-CACTCTGGGACTTGGGATG-3′
Reverse5′-CAGGC AAGAGGGAGTTACAA-3′
GAPDHForward5′-CAGCCTCGTCTCATAGACAAGATG-3′
Reverse5′-CAATGTCCACTTTGTCACAAGAGAA-3′
LrgForward5′-GGAGCAGCTATGGTCTCTTG-3′
Reverse5′-AGTATCAGGCATTCCTTGAG-3′
Scgb3a1Forward5′-CTCAACCCGCTGAAGCTC-3′
Reverse5′-CTTCTGGGAGCCCTCTATGA-3′
Pglyrp1Forward5′-GTGGTGATCTCACACACAGC-3′
Reverse5′-GTGTGGTCACCCTTGATGTT-3′

Share and Cite

MDPI and ACS Style

Zheng, R.; Zhang, Z.-H.; Zhao, Y.-X.; Chen, C.; Jia, S.-Z.; Cao, X.-C.; Shen, L.-M.; Ni, J.-Z.; Song, G.-L. Transcriptomic Insights into the Response of the Olfactory Bulb to Selenium Treatment in a Mouse Model of Alzheimer’s Disease. Int. J. Mol. Sci. 2019, 20, 2998. https://doi.org/10.3390/ijms20122998

AMA Style

Zheng R, Zhang Z-H, Zhao Y-X, Chen C, Jia S-Z, Cao X-C, Shen L-M, Ni J-Z, Song G-L. Transcriptomic Insights into the Response of the Olfactory Bulb to Selenium Treatment in a Mouse Model of Alzheimer’s Disease. International Journal of Molecular Sciences. 2019; 20(12):2998. https://doi.org/10.3390/ijms20122998

Chicago/Turabian Style

Zheng, Rui, Zhong-Hao Zhang, Yu-Xi Zhao, Chen Chen, Shi-Zheng Jia, Xian-Chun Cao, Li-Ming Shen, Jia-Zuan Ni, and Guo-Li Song. 2019. "Transcriptomic Insights into the Response of the Olfactory Bulb to Selenium Treatment in a Mouse Model of Alzheimer’s Disease" International Journal of Molecular Sciences 20, no. 12: 2998. https://doi.org/10.3390/ijms20122998

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop